Drug intelligence / Profile preview

SVX-XP

Development stage: Preclinical
Lead developer: Vaxcyte
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**SVX-XP** is an investigational pneumococcal conjugate vaccine (PCV) in preclinical development by Vaxcyte (formerly SutroVax). Designed as a successor to the company's lead candidate SVX-24, it targets at least 30 pneumococcal serotypes, including emerging strains responsible for invasive pneumococcal disease (IPD) and antibiotic resistance, aiming to provide broader protection than current standards like Prevnar 13 (13 serotypes) and Pneumovax 23 (23 serotypes). It leverages a scalable conjugate platform to minimize carrier suppression while maintaining immunogenicity, with preclinical proof-of-concept demonstrating potential superiority in immune responses.[3][5][7]

Other names: SVX-24 franchise extensionSVX24 franchise extensionSVX 24 franchise extension

Beyond the preview

Go deeper on SVX-XP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SVX-XP.

Explore the full profile